Advertisement
Advertisement
U.S. Markets open in 2 hrs 55 mins
Advertisement
Advertisement
Advertisement
Advertisement

Interpace Biosciences, Inc. (IDXG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.81-0.14 (-2.01%)
At close: 03:59PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

    PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. Under the terms of the Rights Offering, the Company is distributing non-transferable subscription rights to each holder of its common stock as well as to each holder of its outstanding warrants to purchase common stock in each case held as of 5:00 p.m. Eastern

  • GlobeNewswire

    Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering

    Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it has set the record date for its proposed fully back-stopped $30 Million Rights Offering. Under the terms of the Rights Offering, the Company will distribute non-transferable subscription rights to each holder of its common stock as well as to each holder of its ou

  • GlobeNewswire

    Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results

    ●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today an

Advertisement
Advertisement